Lantern Pharma Inc

NASDAQ:LTRNUnited States

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Contact Information

Headquarters

1920 MCKINNEY AVENUE, 7TH FLOORDALLAS, TX, United States 75201

Phone

972-277-1136

Fax

302-655-5049

Executives

Independent Chairman of the Board

Donald Keyser

President, Chief Executive Officer, Director

Panna Sharma

Chief Financial Officer, Secretary

David Margrave

Chief Scientific Officer

Kishor Bhatia

Chief Medical Officer

Marc Chamberlain